Clinics in Dermatology
Volume 27, Issue 5 , Pages 479-484 , September 2009

Cosmeceuticals and silibinin

  • Rana P. Singh, PhD

      Affiliations

    • Cancer Biology Laboratory, 104 School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India
    • Corresponding Author InformationCorresponding authors. Tel.: +91 1126704503; fax: +91 1126742558 (R.P. Singh); Tel.: +1 303 315 1381; fax: +1 303 315 6281 (R. Agarwal).
    • ,
  • Rajesh Agarwal, PhD

      Affiliations

    • Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, C238- P15, Research 2, Room 3121, 12700 19th Avenue, Aurora, CO 80045, USA
    • Corresponding Author InformationCorresponding authors. Tel.: +91 1126704503; fax: +91 1126742558 (R.P. Singh); Tel.: +1 303 315 1381; fax: +1 303 315 6281 (R. Agarwal).

References 

  1. Pinnell SR. Cutaneous photodamage, oxidative stress, and topical antioxidant protection. J Am Acad Dermatol. 2003;48:1–19
  2. Gilchrest BA. A review of skin ageing and its medical therapy. Br J Dermatol. 1996;135:867–875
  3. Choi CM, Berson DS. Cosmeceuticals. Semin Cutan Med Surg. 2006;25:163–168
  4. Pieroni A, Quave CL, Villanelli ML, et al. Ethnopharmacognostic survey on the natural ingredients used in folk cosmetics, cosmeceuticals and remedies for healing skin diseases in the inland Marches, Central-Eastern Italy. J Ethnopharmacol. 2004;91:331–344
  5. Thornfeldt C. Cosmeceuticals containing herbs: fact, fiction, and future. Dermatol Surg. 2005;31:873–880
  6. Wellington K, Jarwis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs. 2001;15:465–489
  7. Davis-Searles PR, Nakanishi Y, Kim NC, et al. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells. Cancer Res. 2005;65:4448–4457
  8. Carini R, Comoglio A, Albano E, et al. Lipid peroxidation and irreversible damage in the rat hepatocyte model: Protection by the silybin-phospholipid complex IdB 1016. Biochem Pharm. 1992;43:2111–2115
  9. Vogel G, Trost W, Braatz R. Pharmacodynamics, site and mechanism of action of silymarin, the antihepatoxic principle from Silybum mar. (L) Gaertn. 1. Acute toxicology or tolerance, general and specific (liver-) pharmacology. Arzneimittelforsch. 1975;25:82–89
  10. Trinchet JC, Coste T, Levy VG, et al. Treatment of alcoholic hepatitis with silymarin. A double-blind comparative study in 116 patients. Gastroenterol Clin Biol. 1989;13:120–124
  11. Pares A, Planas R, Torres M, et al. Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol. 1998;28:615–621
  12. Singh RP, Agarwal R. Flavonoid antioxidant silymarin and skin cancer. Antioxid Redox Signal. 2002;4:655–663
  13. Singh RP, Dhanalakshmi S, Tyagi AK, et al. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. Cancer Res. 2002;62:3063–3069
  14. Singh RP, Deep G, Chittezhath M, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst. 2006;98:846–855
  15. Singh RP, Agarwal R. Mechanisms and preclinical efficacy of silibinin in preventing skin cancer. Eur J Cancer. 2005;41:1969–1979
  16. Matsumura Y, Ananthaswamy HN. Toxic effects of ultraviolet radiation on the skin. Toxicol Appl Pharmacol. 2004;195:298–308
  17. Lang I, Nekam K, Gonzalez-Cabello R, et al. Hepatoprotective and immunological effects of antioxidant drugs. Tokai J Exp Clin Med. 1990;15:123–127
  18. Bowler RM, Gysens S, Hartney C, et al. Increased medication use in a community environmentally exposed to chemicals. Ind Health. 2002;40:335–344
  19. Singh RP, Agarwal R. . SENCAR mouse skin tumorigenesis model. In:  Teicher BA editors. Tumor models in cancer research. Totowa (NJ): Humana Press; 2001;p. 359–380
  20. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, et al. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in the SENCAR mouse skin tumorigenesis model. Cancer Res. 1999;59:622–632
  21. Zhao J, Lahiri-Chatterjee M, Sharma Y, et al. Inhibitory effect of a flavonoid antioxidant silymarin on benzoyl peroxide-induced tumor promotion, oxidative stress and inflammatory responses in SENCAR mouse skin. Carcinogenesis. 2000;21:811–816
  22. Zi X, Mukhtar H, Agarwal R. Novel cancer chemopreventive effects of a flavonoid antioxidant silymarin: inhibition of mRNA expression of an endogenous tumor promoter TNFa. Biochem Biophys Res Commun. 1997;239:334–339
  23. Harris RB, Alberts DS. Strategies for skin cancer prevention. Int J Dermatol. 2004;43:243–251
  24. Witz G. Active oxygen species as factors in multistage carcinogenesis. Proc Exp Biol Med. 1991;198:675–682
  25. Zhao J, Sharma Y, Agarwal R. A Flavonoid antioxidant, silymarin, affords significant inhibition against 12-O-tetradecanoylphorbol 13-acetate-caused modulation of antioxidant and inflammatory enzymes, and cyclooxygenase 2 and interlukin-1a expression in SENCAR mouse epidermis: implications in the prevention of stage I tumor. Mol Carcinog. 1999;26:321–333
  26. Bradley PP, Priebat DA, Christensen RD, et al. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206–209
  27. Marks F, Furstenberger G, Muller-Decker K. Arachidonic acid metabolism as a reporter of skin irritancy and target of cancer chemoprevention. Toxicol Lett. 1998;96-97:111–118
  28. Brecher AR. The role of cyclooxygenase-2 in the pathogenesis of skin cancer. J Drugs Dermatol. 2002;1:44–47
  29. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signaling. Nat Rev Cancer. 2004;4:23–35
  30. Katiyar SK, Korman NJ, Mukhtar H, et al. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst. 1997;89:56–66
  31. Mallikarjuna G, Dhanalakshmi S, Singh RP, et al. Silibinin protects against photocarcinogenesis via modulation of cell cycle regulators, mitogen-activated protein kinases, and Akt signaling. Cancer Res. 2004;64:6349–6356
  32. Pourzand C, Tyrrell RM. Apoptosis, the role of oxidative stress and the example of solar UV radiation. Photochem Photobiol. 1999;70:380–390
  33. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature. 1994;372:773–776
  34. Dhanalakshmi S, Mallikarjuna GU, Singh RP, et al. Silibinin prevents ultraviolet radiation-caused skin damages in SKH-1 hairless mice via a decrease in thymine dimer positive cells and an up-regulation of p53-p21/Cip1 in epidermis. Carcinogenesis. 2004;25:1459–1465
  35. Gu M, Dhanalakshmi S, Singh RP, et al. Dietary feeding of silibinin prevents early biomarkers of UVB radiation-induced carcinogenesis in SKH-1 hairless mouse epidermis. Cancer Epidemiol Biomarkers Prev. 2005;14:1344–1349
  36. Dhanalakshmi S, Agarwal C, Singh RP, et al. Silibinin up-regulates DNA-protein kinase-dependent p53 activation to enhance UVB-induced apoptosis in mouse epithelial JB6 cells. J Biol Chem. 2005;280:20375–20383
  37. Dhanalakshmi S, Mallikarjuna GU, Singh RP, et al. Dual-efficacy of silibinin in protecting or enhancing ultraviolet B radiation-caused apoptosis in human immortalized keratinocyte HaCaT cells. Carcinogenesis. 2004;25:99–106
  38. Ramzi ST, Maruno M, Khaskhely NM, et al. An assessment of the malignant potential of actinic keratoses and Bowen's disease: p53 and PCNA expression pattern correlate with the number of desmosomes. J Dermatol. 2002;29:562–572
  39. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE. 2003;2003:1–15
  40. Gu M, Dhanalakshmi S, Mohan S, et al. Silibinin inhibits ultraviolet B radiation-induced mitogenic and survival signaling, and associated biological responses in SKH-1 mouse skin. Carcinogenesis. 2005;26:1404–1413
  41. Singh RP, Dhanalakshmi S, Mohan S, et al. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells. Mol Cancer Ther. 2006;5:1145–1153
  42. Huang LC, Clarkin KC, Wahl GM. Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. Proc Natl Acad Sci U S A. 1996;93:4827–4832
  43. Ponten F, Berne B, Ren ZP, et al. Ultraviolet light induces expression of p53 and p21 in human skin: effect of sunscreen and constitutive p21 expression in skin appendages. J Invest Dermatol. 1995;105:402–406
  44. Fotedar R, Bendjennat M, Fotedar A. Role of p21WAF1 in the cellular response to UV. Cell Cycle. 2004;3:134–137
  45. Tornaletti S, Pfeifer GP. UV damage and repair mechanisms in mammalian cells. Bioessays. 1996;18:221–228
  46. Cruz JR, Leverkus PDM, Dougherty I, et al. Thymidine dinucleotides inhibit contact hypersensitivity and activate the gene for tumor necrosis factor alpha1. J Invest Dermatol. 2000;114:253–258
  47. Li G, Ho VC. p53-dependent DNA repair and apoptosis respond differently to high- and low-dose ultraviolet radiation. Br J Dermatol. 1998;139:3–10
  48. de Gruijl FR, van Kranen HJ, Mullenders LH. UV-induced DNA damage, repair, mutations and oncogenic pathways in skin cancer. J Photochem Photobiol B. 2001;63:19–27

PII: S0738-081X(09)00127-8

doi: 10.1016/j.clindermatol.2009.05.012

Clinics in Dermatology
Volume 27, Issue 5 , Pages 479-484 , September 2009

Article Tools

* Image Usage & Resolution